Pemphigus Vulgaris - Pipeline Insight, 2025

The “Pemphigus Vulgaris - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Pemphigus Vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pemphigus Vulgaris: Understanding

Pemphigus Vulgaris: Overview

Pemphigus vulgaris is a severe autoimmune disorder characterized by the formation of blisters and erosions on the skin and mucous membranes. This condition arises when the body's immune system mistakenly produces antibodies against desmogleins, which are proteins critical for the adhesion of epidermal cells. As a result, the loss of cell-to-cell adhesion within the epidermis leads to the formation of fragile, flaccid blisters that rupture easily, causing painful sores and erosions. This condition occurs when the immune system produces autoantibodies against desmogleins, specifically desmoglein 1 and desmoglein 3, which are critical adhesion proteins in the epidermis. Beyond the visible symptoms, pemphigus vulgaris can have systemic effects. Patients often experience general malaise, fatigue, and weight loss due to the chronic pain and difficulty in eating. The emotional and psychological impact of living with a chronic, painful, and disfiguring disease can be profound, leading to anxiety, depression, and a reduced quality of life. The disease's chronic nature requires long-term management, typically involving immunosuppressive medications to control the immune system's aberrant activity and prevent further blistering and erosions.

As the disease progresses, blisters start to form on the skin. These blisters can appear anywhere but are most common on the scalp, face, chest, back, and groin. The blisters are typically soft, filled with fluid, and very fragile, often bursting with minimal trauma. When they rupture, they leave behind raw, painful erosions that can easily become infected. These skin erosions can be widespread and may merge, covering large areas of the body. The skin lesions are often slow to heal, which can lead to chronic wounds and increased susceptibility to secondary infections.

The diagnosis of PV is based on a combination of clinical presentation and detection of tissue-bound and/or circulating autoantibodies. The gold standard diagnostic of PV is direct immunofluorescence (DIF) microscopy, which can detect tissue-bound autoantibodies. In pemphigus, DIF microscopy reveals intercellular binding of IgG and/or C3 within the epidermis and/or epithelium. Cytological examination (Tzanck smear) is useful for the rapid demonstration of acantholytic keratinocytes of the spinous layer (abundant eosinophilic cytoplasm and rounded central nucleus), stained preferably by hematoxylin and eosin.

'Pemphigus Vulgaris- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pemphigus Vulgaris pipeline landscape is provided which includes the disease overview and Pemphigus Vulgaris treatment guidelines. The assessment part of the report embraces, in depth Pemphigus Vulgaris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pemphigus Vulgaris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pemphigus Vulgaris R&D. The therapies under development are focused on novel approaches to treat/improve Pemphigus Vulgaris.

Pemphigus Vulgaris Emerging Drugs Chapters

This segment of the Pemphigus Vulgaris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pemphigus Vulgaris Emerging Drugs

Efgartigimod PH20: Argenx

VYVGART (efgartigimod alfa injection) is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. It is the first approved FcRn blocker for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive. Efgartigimod SC is a subcutaneous product including efgartigimod alfa injection, a human IgG1 antibody fragment, and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE drug delivery technology to facilitate subcutaneous delivery of biologics. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Pemphigus Vulgaris.

SN1011: SinoMab Bioscience

SN1011 is the third generation, covalent reversible BTK inhibitor with improved safety, higher selectivity and superior efficacy and for the long-term treatment of systemic lupus erythematous, pemphigus vulgaris, multiple sclerosis, rheumatoid arthritis, and other immunological diseases. SN1011 differentiates from existing BTK inhibitors currently available in the market in terms of mechanism of action, affinity, selectivity and safety. Currently, the drug is in the Phase II stage of its development for the treatment of Pemphigus vulgaris.

AlloNK: Artiva Biotherapeutics

AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). The company believes the compelling cell killing properties of NK cells, when combined with mAbs for targeting, creates an opportunity to generate potentially transformative therapies. Currently, the drug is in the Phase I stage of its development for the treatment of Pemphigus vulgaris.

Pemphigus Vulgaris: Therapeutic Assessment

This segment of the report provides insights about the different Pemphigus Vulgaris drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pemphigus Vulgaris

• There are approx. 8+ key companies which are developing the therapies for Pemphigus Vulgaris. The companies which have their Pemphigus Vulgaris drug candidates in the most advanced stage, i.e. Phase III include, Argenx.

Phases

The report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pemphigus Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pemphigus Vulgaris: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pemphigus Vulgaris therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pemphigus Vulgaris drugs.

Pemphigus Vulgaris Report Insights

• Pemphigus Vulgaris Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pemphigus Vulgaris Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pemphigus Vulgaris drugs?
• How many Pemphigus Vulgaris drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pemphigus Vulgaris?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pemphigus Vulgaris therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pemphigus Vulgaris and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Argenx
• SinoMab Bioscience
• Cabaletta Bio
• Artiva Biotherapeutics

Key Products

• Efgartigimod PH20
• SN1011
• DSG3-CAART
• AlloNK

This product will be delivered within 2 business days.